Diabetic Macular Edema – Epidemiology – Epidemiology – Diabetic Macular Edema – Mature Markets

Clarivate Epidemiology’s coverage of diabetic macular edema comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of diabetic macular edema for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a 20-year period for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.

Clarivate Epidemiology’s diabetic macular edema forecast will answer the following questions:

• Of all people with diabetic macular edema, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with diabetic macular edema, how many in each country across the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of diabetic macular edema over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts nine diabetic macular edema patient populations, as follows:

• Total DME prevalent cases
• Center-involved DME cases
• Non-center-involved DME cases
• Mixed DME cases
• DME with mild-moderate non-proliferative diabetic retinopathy
• DME with severe non-proliferative diabetic retinopathy
• DME with proliferative diabetic retinopathy
• Diagnosed DME prevalent cases
• Undiagnosed DME prevalent cases
• Diagnosed drug-treated DME cases

Note: Coverage may vary by country.